Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
10.49
+0.10 (0.96%)
At close: Apr 22, 2026, 4:00 PM EDT
10.68
+0.19 (1.80%)
After-hours: Apr 22, 2026, 7:59 PM EDT
Zevra Therapeutics Employees
Zevra Therapeutics had 61 employees as of December 31, 2025. The number of employees increased by 2 or 3.39% compared to the previous year.
Employees
61
Change (1Y)
2
Growth (1Y)
3.39%
Revenue / Employee
$1,745,410
Profits / Employee
$1,271,885
Market Cap
615.88M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 61 | 2 | 3.39% | 61 | 0 |
| Dec 31, 2024 | 59 | -10 | -14.49% | 59 | 0 |
| Dec 31, 2023 | 69 | 33 | 91.67% | 65 | 4 |
| Dec 31, 2022 | 36 | 12 | 50.00% | 32 | 4 |
| Dec 31, 2021 | 24 | 2 | 9.09% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| CorMedix | 191 |
| Rigel Pharmaceuticals | 174 |
| Absci | 140 |
| Kyverna Therapeutics | 130 |
| Ocugen | 116 |
| Adlai Nortye | 109 |
| Aclaris Therapeutics | 73 |
ZVRA News
- 4 weeks ago - Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call - GlobeNewsWire
- 2 months ago - Zevra Therapeutics to Present at the Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 2 months ago - Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ - GlobeNewsWire
- 2 months ago - Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 - GlobeNewsWire